中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.016 seconds)

    T CELL RECEPTORS
    3.
    发明申请
    T CELL RECEPTORS 审中-公开
    细胞受体

    公开(公告)号：WO2013041865A1

    公开(公告)日：2013-03-28

    申请号：PCT/GB2012/052322

    申请日：2012-09-20

    Applicant: IMMUNOCORE LIMITED ,  JAKOBSEN, Bent Karsten ,  LIDDY, Nathaniel Ross ,  VUIDEPOT, Annelise Brigitte ,  MOLLOY, Peter Eamon

    Inventor： JAKOBSEN, Bent Karsten ,  LIDDY, Nathaniel Ross ,  VUIDEPOT, Annelise Brigitte ,  MOLLOY, Peter Eamon

    IPC: C07K14/705

    CPC classification number: C07K14/7051 ,  C07K2319/30

    Abstract: The present invention relates to T cell receptors (TCRs) that the property of binding to EVDPIGHLY (SEQ ID No: 1) HLA-A1 complex and comprise a TCR alpha chain variable domain and a TCR beta chain variable domain. The EVDPIGHLY peptide is derived from the MAGE-3 protein which is expressed in many tumour types, including melanomas, and other solid tumours such as Head and Neck Squamous Cell, lung, bladder, gastric, prostate, colorectal and esophageal carcimomas. Also provided are nucleic acids encoding such TCRs, cells presenting such TCRs and pharmaceutical compositions comprising such TCRs.

    Abstract translation: 本发明涉及结合EVDPIGHLY（SEQ ID No：1）HLA-A1复合物并包含TCRα链可变结构域和TCRβ可变结构域的特性的T细胞受体（TCR）。 EVDPIGHLY肽衍生自MAGE-3蛋白，其在许多肿瘤类型中表达，包括黑素瘤和其他实体瘤如头颈部鳞状细胞，肺，膀胱，胃，前列腺，结肠直肠和食管癌。 还提供了编码这种TCR的核酸，呈现这种TCR的细胞和包含这种TCR的药物组合物。

    CELLS TRANSFORMED WITH NUCLEIC ACID ENCODING NY-ESO T CELL RECEPTORS
    4.
    发明申请
    CELLS TRANSFORMED WITH NUCLEIC ACID ENCODING NY-ESO T CELL RECEPTORS 审中-公开
    用核酸编码NY-ESO T细胞受体的细胞转化

    公开(公告)号：WO2008037943A1

    公开(公告)日：2008-04-03

    申请号：PCT/GB2006/003649

    申请日：2006-09-29

    Applicant: MEDIGENE LIMITED ,  JAKOBSEN, Bent, Karsten ,  BOULTER, Jonathan, Michael ,  LI, Yi ,  MOLLOY, Peter, Eamon ,  DUNN, Steven, Mark

    Inventor： JAKOBSEN, Bent, Karsten ,  BOULTER, Jonathan, Michael ,  LI, Yi ,  MOLLOY, Peter, Eamon ,  DUNN, Steven, Mark

    IPC: C07K14/705

    CPC classification number: C07K14/70503

    Abstract: The present invention provides cells transformed with expressible nucleic acids encoding a TCR specific for the SLLMWITQC-HLA-A*0201 complex, said nucleic acids consisting of: (i) a sequence comprising bases 15 to 836 of SEQ ID Nos: 1, 3, 5, 7, or 9, and (ii) a sequence comprising bases 16 to 948 of SEQ ID Nos: 11, 13, 15, 17, 19, or 21 or; (a) a sequence comprising bases 15 to 836 of SEQ ID Nos: 23, 25, 27, 29 or 31 and (b) a sequence comprising bases 16 to 948 of SEQ ID Nos: 33, 35, 37, 39, 41, or 43. Such cells are useful for targeting NY-ESO + cancer cells presenting the SLLMWITQC-HLA-A*0201 complex.

    Abstract translation: 本发明提供用编码针对SLLMWITQC-HLA-A * 0201复合物的TCR特异性的可表达核酸转化的细胞，所述核酸由以下组成：（i）包含SEQ ID No：1,3， 5，7或9，和（ii）包含SEQ ID NO：11,13,15,17,19或21的碱基16至948的序列; （a）包含SEQ ID No：23,25,27,29或31的碱基15至836的序列和（b）包含SEQ ID No：33,35,37,39,41， 这种细胞可用于靶向呈现SLLMWITQC-HLA-A * 0201复合物的NY-ESO +癌细胞。

Patent Agency Ranking